The multiple actions of angiotensin II in atherosclerosis.
about
How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trialAzilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review StudyCan Aliskiren be Considered as a New Novel Drug for Hypertension?Reactive Oxygen Species: A Key Hallmark of Cardiovascular DiseaseRedox Roles of Reactive Oxygen Species in Cardiovascular DiseasesAngiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signalingLow dietary vitamin D in mid-life predicts total mortality in men with hypertension: the Honolulu heart program.Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patientsRenin-angiotensin-aldosterone system blockade for cardiovascular diseases: current statusCross-talk between angiotensin II and IGF-1-induced connexin 43 expression in human saphenous vein smooth muscle cells.Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts.The potential role of AT(1)-receptor blockade in the prevention and reversal of atherosclerosis.Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 13,4-Di-O-Caffeoylquinic Acid Inhibits Angiotensin-II-Induced Vascular Smooth Muscle Cell Proliferation and Migration by Downregulating the JNK and PI3K/Akt Signaling Pathways.Impaired glutathione redox system paradoxically suppresses angiotensin II-induced vascular remodeling.Abundant pleiotropy in human complex diseases and traits.Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis.High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.TGRL Lipolysis Products Induce Stress Protein ATF3 via the TGF-β Receptor Pathway in Human Aortic Endothelial CellsEffect of paricalcitol and enalapril on renal inflammation/oxidative stress in atherosclerosis.Role of matrix Gla protein in angiotensin II-induced exacerbation of vascular calcification.Pharmacological basis of different targets for the treatment of atherosclerosis.Spotlight on endothelial progenitor cell inhibitors: short review.DNA damage and augmented oxidative stress in bone marrow mononuclear cells from Angiotensin-dependent hypertensive mice.The Role of SIRT3 in Mediating Cardioprotective Effects of RAS Inhibition on Cardiac Ischemia-Reperfusion.Coronary constriction to angiotensin II is enhanced by endothelial superoxide production in sheep programmed by dexamethasone.The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studiesAngiotensin II type 1 receptor 1166C polymorphism is associated with abdominal aortic aneurysm in three independent cohorts.Cardiovascular morbidity and mortality and renal artery stenosis.The forgotten face of regular physical exercise: a 'natural' anti-atherogenic activity.Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview.Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.Depression and cardiovascular disease in women: is there a common immunological basis? A theoretical synthesis.The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the IkappaB kinase complex.The anti-atherosclerotic di-peptide, Trp-His, inhibits the phosphorylation of voltage-dependent L-type Ca(2+) channels in rat vascular smooth muscle cells.Angiotensin II Destabilizes Coronary Plaques in Watanabe Heritable Hyperlipidemic RabbitsEffects of angiotensin II on connexin 43 of VSMCs in arteriosclerosis.Involvement of glycogen synthase kinase-3beta in palmitate-induced human umbilical vein endothelial cell apoptosis.
P2860
Q24793341-35F9A28A-2568-49F9-81B1-F124CD72EDB3Q26740629-9EDAE973-9A89-437B-934A-303AF2906816Q26775106-F22DF9B9-99B5-4ABC-8390-B2FE89BB2746Q28076240-D17ABA7C-85F2-4C82-AA26-E5CFF6085A16Q28082072-97F37DFC-D0FF-4AD2-AA73-5F56B1F318C5Q28575995-C54474F3-E4C5-4740-B8BD-81F0C7745A01Q30359753-F0E6F225-F51E-429B-A505-2E317D4E1A99Q33765684-5E981956-C183-4FC2-B191-0000955F2977Q34124779-0965BECC-E11B-4CA1-8075-96D86D173B82Q34398211-D525CD6B-3BAB-4E02-BA51-A6887E49161CQ34429685-8FDD98A0-CF8A-4888-B011-56B4FE7409A6Q34521975-E6F7E29A-E064-43F6-9BF0-0152A00A4576Q34761170-82AE8A08-CA3B-4511-B9C1-B15FE2452919Q34780141-30D3CF5C-B07E-498F-841A-79F9E9E33253Q35106662-6DB126F3-50B9-4A79-A5AA-C04EFA548439Q35364697-0F8C142C-8027-49CB-B85D-3B8FA8D0ED02Q35542127-09B3627D-C893-42FB-A829-175F7C13E6A9Q35581709-C3CDF5BB-6F0A-4B95-82F4-173503895ED9Q35606860-F5B87E7D-9B8E-44FC-9466-43AE4DC3B553Q35879314-D7427ED8-3C00-48D2-B671-CE3D2E9E2D98Q35996673-E7D2A4FF-2B26-4549-90D6-8BF24E4F9505Q36309309-15BA3529-4CF4-4679-9139-F3C5120B2370Q36346487-9669ECDE-0927-4336-B32B-DF37706C00A9Q36381012-D480E93C-80B3-4A03-8423-C1EC455F6251Q36651392-5333344F-FB83-49F9-B29E-4B67BC6218DEQ36793759-27B01B5D-F80A-47C3-8E79-D8A1CFC08ECDQ36873843-92237BEB-4A54-4969-A812-780B8BC5EC34Q37019887-01B7DE8F-68EF-4077-A03E-896BED5FC992Q37158159-D50F3251-BFB9-4665-8BCC-C2561806E1DBQ37415982-90973016-ACC7-4BF6-B961-CBC81585C062Q37633683-FF5CF168-B5EF-4599-8770-410C1C1E5753Q37897619-15D196EE-8907-49CE-8C58-D7132A460303Q38020901-5EAC465D-04FB-445B-A455-3010022FC571Q38079623-F60ACF10-BB39-4376-96BB-91477504095BQ38186686-B9A1DC56-54DC-4934-8276-3CD91988501BQ40309305-9B731F60-C1C0-4DE0-A00A-8A66F7C6E877Q40317454-B046C044-E26E-496A-A50E-E578147FAE60Q40783940-FB96D71A-4B4D-41CD-9053-5F76BAD1B848Q41983145-0637C56C-706E-472B-BCE8-170A241E1241Q44171222-749A2C10-7406-443E-A839-4C4F4230D1E9
P2860
The multiple actions of angiotensin II in atherosclerosis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The multiple actions of angiotensin II in atherosclerosis.
@ast
The multiple actions of angiotensin II in atherosclerosis.
@en
The multiple actions of angiotensin II in atherosclerosis.
@nl
type
label
The multiple actions of angiotensin II in atherosclerosis.
@ast
The multiple actions of angiotensin II in atherosclerosis.
@en
The multiple actions of angiotensin II in atherosclerosis.
@nl
prefLabel
The multiple actions of angiotensin II in atherosclerosis.
@ast
The multiple actions of angiotensin II in atherosclerosis.
@en
The multiple actions of angiotensin II in atherosclerosis.
@nl
P2093
P1433
P1476
The multiple actions of angiotensin II in atherosclerosis.
@en
P2093
Kagiyama S
Phillips MI
Schmidt-Ott KM
P356
10.1016/S0167-0115(00)00178-6
P577
2000-09-01T00:00:00Z